apprenticesis worked on some of their projects, like the guggenheim museum in new york city.s is where all of the work was completed. mostg one of wright's prolific periods in his life. space baseding this on the work you are doing here. when you walk into this space, you see the drafting tables, you see the roof, which creates this beautiful filtered light. not revealed is until you sit down at your drafting table, and the landscap e comes in through the windows. he will use low roofs to frame views, and really choreograph your experience. after his passing in 1959, the apprentices here continued his created an associated architects firm, which continued to work through the 60's through ehe 1990's, and continued th learn-by-doing model. of theests take a tour , we want people to think of this idea of thinking outside of the locks, creating a risk that will enhance your life. ight came out here at a time when he was 70 years old. he started something completely new. one of the things we like to say is that wright persevered in everything that he did. he worked to move archite

guggenheim, not the museum but the firm, piper and morgan stanley all say, yes, this is the one to buyw, obviously the corollary is bristol-myers opdivo not doing well. but i like the fact what could happen here is if there's somehow this is something allergan's been talking about, brent saunders, somehow a distinction between older drugs and price competition and newer drugs and unfeddered prices because it's so expensive to bring a ketruda that -- i ain't going up the golden elevator that i've seen, but these analysts are saying, okay, use i think the decline in pharma to buy merck. merck would have been up a lot more had the press conference not occurred. >> and it was prior to his comments. >> yes. the press conference was a bit of a damper on drug stocks including merck everyone though this was a huge win in front of the fda. people are not understanding -- now, look, bristol-myers can come back with some combination, but it's an amazing drug. it's a wonder drug and costs a fortune to develop. and you don't want to stifle that innovation. >> all right. we got the opening bell abou

guggenheim foundation and in 1997-98 he was awarded the jb senior scholarship. senior in stature, not age. [laughter] >> he also serves as chairman of the museum academic any. in peter's new book why explaining the holocaust he dispelled many misconceptions and answered some the most basic questions that remain, why the jews and not another ethnic group, why the germans, why such a swift and sweeping extermination, why didn't-- did it more jews fight back more often? why did they receive more help? while responding has been most frequently asked and peter brings a wealth of experience on conventional popular views of the history, challenging some of the most prominent recent interpretation and argues there's no single theory that explains the holocaust, rather the convergence of multiple forces at a moment in time that led to the test-- catastrophe. he will share the main point of this book while also offering a behind-the-scenes look detailing why he wrote his new book and why it took the form it did. it is now my great pleasure to welcome peter hayes to the stage [applause]. >> good evening and thank you all for coming out on a rainy night at a busy week